is reporting from
AstraZeneca Announces First Patient Enrolled in Head-to-Head Comparison of CRESTOR/Ezetimibe
uusjio | September 6, 2007 at 07:43 pmby
399 views | 0 Recommendations | 0 comments
AstraZeneca today announced enrolment of the first patient in the new GRAVITY study (Gauging the lipid effects of RosuvAstatin plus ezetimibe Versus sImvastatin plus ezetimibe TherapY). GRAVITY is a clinical trial examining the impact on LDL-cholesterol ('bad' cholesterol) levels in patients with hypercholesterolaemia and coronary heart disease following a treatment regimen with lower doses of CRESTOR plus ezetimibe, compared to higher doses of simvastatin plus ezetimibe (in a fixed dose combination marketed as Vytorin(TM) or Inegy(TM)). Ezetimibe is a cholesterol absorption inhibitor and this study is AstraZeneca's first head-to-head comparison of CRESTOR/ezetimibe with simvastatin/ezetimibe.